Edina Q. Wang

35 Stirling Highway
Crawley, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Targeting of the oncogenic fusion EWSR1-FLI1 in Ewing Sarcoma by CRISPR/dCas9 silencers.

Targeting of the oncogenic fusion EWSR1-FLI1 in Ewing Sarcoma by CRISPR/dCas9 silencers.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 07, 2025

Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.

Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 16, 2024

Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer.

Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 20, 2023

Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor.

Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor.

Journal: International journal of molecular sciences

Published: March 25, 2021

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.

Journal: Nature communications

Published: October 31, 2020

Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment.

Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment.

Journal: Expert opinion on drug delivery

Published: August 25, 2020

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.

Journal: Biomolecules

Published: December 20, 2019

Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.

Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.

Journal: NPJ precision oncology

Published: October 09, 2019

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

Journal: Oncogene

Published: July 24, 2019

Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.

Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.

Journal: Journal of gynecologic oncology

Published: June 17, 2019

Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

Journal: Chemical science

Published: March 28, 2019

Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.

Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: September 19, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026